Zelira Therapeutics ( (AU:ZLD) ) has issued an update.
Zelira Therapeutics has secured a fourth funding tranche of US$681,000, bringing the total to US$3.25 million to support FDA clinical trials for its HOPE® 1 product. This funding is managed through a special purpose vehicle and underscores FDA’s support for the program targeting Phelan-McDermid Syndrome and Autism Spectrum Disorder. The FDA’s feedback has helped Zelira outline its Phase 1 study, marking a significant step towards addressing unmet medical needs. Zelira continues fundraising efforts to drive its clinical program forward.
More about Zelira Therapeutics
Zelira Therapeutics is a global biopharmaceutical company that focuses on the research, development, and commercialization of clinically validated cannabinoid-based medicines. The company owns a portfolio of proprietary products and is involved in clinical development for global market entry. Zelira is committed to developing cannabinoid-based medicines for various medical conditions, including insomnia, autism, and chronic pain, and also offers over-the-counter products.
YTD Price Performance: -4.94%
Average Trading Volume: 421
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.1M
For detailed information about ZLD stock, go to TipRanks’ Stock Analysis page.